

Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

CD3 Antibody, anti-human, VioBlue®, REAfinity™

RRID:AB_2726687

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-114-519, RRID:AB_2726687

Antibody Information

URL: http://antibodyregistry.org/AB_2726687

Proper Citation: Miltenyi Biotec Cat# 130-114-519, RRID:AB_2726687

Target Antigen: CD3

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-460. (RRID:AB_2657065).

Antibody Name: CD3 Antibody, anti-human, VioBlue®, REAfinity™

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: clone REA613

Antibody ID: AB_2726687

Vendor: Miltenyi Biotec

Catalog Number: 130-114-519

Record Creation Time: 20250820T003100+0000

Record Last Update: 20250820T082835+0000

Ratings and Alerts

No rating or validation information has been found for CD3 Antibody, anti-human, VioBlue®, REAfinity™.

No alerts have been found for CD3 Antibody, anti-human, VioBlue®, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Vandoren R, et al. (2026) AIRRWAS integrates TCR-microbiome data to reveal how the gut microbiome shapes the circulating and mucosal T cell repertoire. Cell reports, 45(6), 117479.

Desveaux JM, et al. (2026) Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of Pseudomonas aeruginosa act through distinct mechanisms. eLife, 14.

David M, et al. (2025) Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs. Molecular therapy. Oncology, 33(2), 200989.